Literature DB >> 9021180

A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques.

K K Van Rompay1, J L Greenier, M L Marthas, M G Otsyula, R P Tarara, C J Miller, N C Pedersen.   

Abstract

The simian immunodeficiency virus (SIV)-newborn rhesus macaque model of AIDS can be used to study directly the virulence of viral mutants which are resistant to antiviral drugs. A viral mutant called SIVmac79A6.1, isolated from an SIV-infected macaque after prolonged zidovudine treatment, was found to have a double-base-pair change at codon 151 of reverse transcriptase, resulting in a glutamine to methionine substitution (Q151M). This mutation was associated with more than 100-fold increased resistance to zidovudine and low-level cross-resistance to other dideoxynucleoside analogs. To determine whether this Q151M mutation affects viral virulence, four newborn macaques were inoculated intravenously with a biological clone of this drug-resistant SIVmac79A6.1 mutant; two of these animals were also treated orally with zidovudine. All four animals showed persistent viremia, and two of the four animals developed fatal immunodeficiency at 3 and 8 months of age, respectively. The remaining two animals had CD4+ T-cell depletion and clinical symptoms of AIDS at 22 months. No phenotypic or genotypic reversion of virus to the wild type could be detected in any of the four animals. These results demonstrate that the Q151M mutation in SIV reverse transcriptase does not reduce viral virulence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021180      PMCID: PMC163702     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.

Authors:  A Erice; D L Mayers; D G Strike; K J Sannerud; F E McCutchan; K Henry; H H Balfour
Journal:  N Engl J Med       Date:  1993-04-22       Impact factor: 91.245

2.  Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.

Authors:  M T Ogino; W M Dankner; S A Spector
Journal:  J Pediatr       Date:  1993-07       Impact factor: 4.406

3.  Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.

Authors:  K K Van Rompay; M G Otsyula; M L Marthas; C J Miller; M B McChesney; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.

Authors:  J S Montaner; J Singer; M T Schechter; J M Raboud; C Tsoukas; M O'Shaughnessy; J Ruedy; K Nagai; H Salomon; B Spira
Journal:  AIDS       Date:  1993-02       Impact factor: 4.177

5.  Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.

Authors:  T Shirasaka; R Yarchoan; M C O'Brien; R N Husson; B D Anderson; E Kojima; T Shimada; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

6.  Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection.

Authors:  K K Van Rompay; M L Marthas; R A Ramos; C P Mandell; E K McGowan; S M Joye; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

8.  Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

Authors:  S H Cheeseman; D Havlir; M M McLaughlin; T C Greenough; J L Sullivan; D Hall; S E Hattox; S A Spector; D S Stein; M Myers
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-02-01

Review 9.  Clinical correlates and molecular basis of HIV drug resistance.

Authors:  M A Wainberg; Z Gu; Q Gao; E Arts; R Geleziunas; S Bour; R Beaulieu; C Tsoukas; J Singer; J Montaner
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993

Review 10.  Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.

Authors:  V A Johnson
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

View more
  10 in total

1.  Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.

Authors:  B Rodés; A Holguín; V Soriano; M Dourana; K Mansinho; F Antunes; J González-Lahoz
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Robert A Smith; Donovan J Anderson; Bradley D Preston
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

Authors:  K K Van Rompay; M D Miller; M L Marthas; N A Margot; P J Dailey; D R Canfield; R P Tarara; J M Cherrington; N L Aguirre; N Bischofberger; N C Pedersen
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Tackling HIV and AIDS: contributions by non-human primate models.

Authors:  Koen K A Van Rompay
Journal:  Lab Anim (NY)       Date:  2017-05-22       Impact factor: 12.625

5.  9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.

Authors:  K K Van Rompay; J M Cherrington; M L Marthas; P D Lamy; P J Dailey; D R Canfield; R P Tarara; N Bischofberger; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

6.  Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.

Authors:  Koen K A Van Rompay; Tim B Matthews; Joanne Higgins; Don R Canfield; Ross P Tarara; Mark A Wainberg; Raymond F Schinazi; Niels C Pedersen; Thomas W North
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.

Authors:  E Cherry; M Slater; H Salomon; E Rud; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Authors:  Koen K A Van Rompay; Raman P Singh; Bapi Pahar; Donald L Sodora; Casey Wingfield; Jonathan R Lawson; Marta L Marthas; Norbert Bischofberger
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.

Authors:  Koen K A Van Rompay; Said Hassounah; Brandon F Keele; Jeffrey D Lifson; Amir Ardeshir; Jennifer Watanabe; Hanh Thi Pham; Elena Chertova; Raymond Sowder; Jan Balzarini; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

10.  Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

Authors:  Koen K A Van Rompay; Jeffrey A Johnson; Emily J Blackwood; Raman P Singh; Jonathan Lipscomb; Timothy B Matthews; Marta L Marthas; Niels C Pedersen; Norbert Bischofberger; Walid Heneine; Thomas W North
Journal:  Retrovirology       Date:  2007-04-06       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.